Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa.

Sponsor

University of Chile (Other)

Overall Status

Enrolling by invitation

CT.gov ID

NCT05288478

Collaborator

Fundación Debra Chile (Other)

100

Enrollment

Location

Arms

10.8

Anticipated Duration (Months)

9.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Inherited Epidermolysis Bullosa (EB) is a disorder that causes skin fragility and blistering in skin and mucous membranes, including the mouth. Recurrent oral blisters and ulcer result in oral pain and discomfort.

Dentoxol® is a mouthrinse that has anti-inflammatory, antimicrobial and analgesic effects. It has significant potential to reduce EB related oral symptoms.

This study includes people living with Inherited Epidermolysis Bullosa aged 6 and above; and is aimed at determining the efficacy of two different dose regimens of Dentoxol mouthrinse in reducing oral symptoms.

Condition or Disease	Intervention/Treatment	Phase
Epidermolysis Bullosa Oral Ulcer	Combination Product: Dentoxol mouthrinse dosages	Phase 2

Detailed Description

Inherited Epidermolysis Bullosa (EB) is a group of genetic disorders with skin fragility and blistering. In addition to the skin, it can affect the mucous membranes, causing oral symptoms including oral pain and discomfort due to recurrent oral blisters, ulcers and erosions. Dentoxol® is a proprietary mouthrinse that has anti-inflammatory, antimicrobial and analgesic effects. This three-pronged strategy therefore has significant potential to reduce EB related oral symptoms.

Preliminary reports of Dentoxol® mouthrinse have suggested that it is safe and effective in reducing the EB related oral symptoms.Therefore, a well-controlled Phase II study is now warranted.

This study will include people living with Inherited Epidermolysis Bullosa aged 6 and over, and seeks to determinate the efficacy of two different dose regimens of Dentoxol mouthrinse in reducing the symptoms mentioned above.

Methods: 100 subjects with EB will be recruited and will be given Dentoxol® mouthrinse for two periods of 6 weeks using different dose regimes.

Subjects will have a dose regimen assigned randomly, group A: first 6 weeks will be asked to rinse 5 times a day, followed by a 4 weeks washout period and the second 6 weeks period: twice a day. Group B: first 6 weeks 2 times a day, second 6 weeks period: 5 times a day, both with a 4 week washout period in between.

On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

100 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Intervention Model Description:

100 subjects with EB will be recruited, divided into groups according to their mayor type of EB and subtype, they will use Dentoxol® mouthrinse twice a day or 5 times each day. Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between. On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist.100 subjects with EB will be recruited, divided into groups according to their mayor type of EB and subtype, they will use Dentoxol® mouthrinse twice a day or 5 times each day. Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between. On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist.

Masking:

Single (Outcomes Assessor)

Primary Purpose:

Supportive Care

Official Title:

Phase II Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in Epidermolysis Bullosa.

Actual Study Start Date :

Apr 6, 2022

Anticipated Primary Completion Date :

Aug 1, 2022

Anticipated Study Completion Date :

Mar 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Group A First 6 weeks they will use the mouthrinse 5 times a day, following 4 week washout period.	Combination Product: Dentoxol mouthrinse dosages Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.
Active Comparator: Group A, second period After the washout period, the next 6 weeks the will use the mouthrinse twice a day. On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist.	Combination Product: Dentoxol mouthrinse dosages Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.
Active Comparator: Group B First 6 weeks they will use the mouthrinse twice a day, following 4 week washout period	Combination Product: Dentoxol mouthrinse dosages Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.
Active Comparator: Group B, second period After the washout period, the next 6 weeks they will use the mouthrinse 5 times a day. On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist.	Combination Product: Dentoxol mouthrinse dosages Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.

Outcome Measures

Primary Outcome Measures

Change in oral symptoms associated to oral bullae, erosions and ulcerations in adults and children over the age of 6 living with Epidermolysis Bullosa with two different dose regimes of Dentoxol® mouthrinse and compare both effects. [16 weeks]
Epidermolysis Bullosa Oral Health Questionnaire (EBOHQ)

Secondary Outcome Measures

Change in the duration of the lesions with two different dose regimes of Dentoxol® mouthrinse and compare both effects. [16 weeks]
Epidermolysis Bullosa Oral Health Questionnaire (EBOHQ) (Validated Questionnaire)
Change in the frequency of the lesions with two different dose regimes of Dentoxol® mouthrinse and compare both effects. [16 weeks]
Epidermolysis Bullosa Oral Health Questionnaire (EBOHQ) (Validated Questionnaire)
Change in the recurrence of the lesions with two different dose regimes of Dentoxol® mouthrinse and compare both effects. [16 weeks]
Epidermolysis Bullosa Oral Health Questionnaire (EBOHQ) (Validated Questionnaire)
Change in the size of the lesions with two different dose regimes of Dentoxol® mouthrinse and compare both effects. [16 weeks]
Epidermolysis Bullosa Oral Health Questionnaire (EBOHQ) (Validated Questionnaire)
Change in the number of the lesions with two different dose regimes of Dentoxol® mouthrinse and compare both effects. [16 weeks]
Epidermolysis Bullosa Oral Health Questionnaire (EBOHQ) (Validated Questionnaire)
Change in the distribution of the lesions with two different dose regimes of Dentoxol® mouthrinse and compare both effects. [16 weeks]
Epidermolysis Bullosa Oral Health Questionnaire (EBOHQ) (Validated Questionnaire)
Change in oral pain with two different dose regimes of Dentoxol® mouthrinse and compare both effects. [16 weeks]
Epidermolysis Bullosa Oral Health Questionnaire (EBOHQ) (Validated Questionnaire)
Improve the oral health related quality of life and oral functioning with two different dose regimes of Dentoxol® mouthrinse and compare both effects. [16 weeks]
Epidermolysis Bullosa Oral Health Questionnaire (EBOHQ) (Validated Questionnaire)
Patients compliance with treatment. [16 weeks]
Daily record of mouthrinse use.
Patients acceptance of mouthrinse use [16 weeks]
Mouthrinse Acceptance Form (Validated Questionnaire)

Eligibility Criteria

Criteria

Ages Eligible for Study:

6 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

People living with Inherited Epidermolysis Bullosa, including all types and subtypes, registered at Debra Foundation at the country of the study.

Exclusion Criteria:

Unable to give written informed consent / assent.
Have used a mouth rinse aimed at managing oral ulcers in the last 4 weeks.
Known allergy/intolerance to any component of the study rinse.
Planning to use any of the following contraindicated medications during the study period (pain medications are allowed)
Any agent marketed for oral mucositis
Steroids
Antibiotics (eg, tetracyclines) (Note: topical antifungals are allowed)
Povidone iodine
Sucralfate and other coating agents such as Gelclair, MuGard, etc.
Caphosol
Chlorhexidine Gluconate (Oralgene, Perioaid, Peridex, Periogard)
Diphenhydramine (Benadryl)
Laser therapy for oral mucositis
Any other anti-inflammatory agent
Any other investigative agent
*Note: "Miracle / Magic" rinse preparations containing viscous lidocaine are allowed, however, diphenhydramine and other excluded agents should not be added.
Age below 6 years
Pregnant or nursing
Unable to rinse the mouth due to limited oral functioning.